While these agents have shown efficacy in the treatment of HER2 overexpressing breast cancer, not all HER2- positive cancers respond even initially to these drugs, and the development of trastuzumab and lapatinib resistance is an additional clinical problem [42]. The gene discussed is ERBB2; the disease is breast cancer.